

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Thursday 9 January, 2025

Aachen, Germany, 09 January 2025 –

Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Canada Incubator, an innovation lab to develop innovative healthcare solutions.

Uli Brödl graduated as a Medical Doctor from Ludwig-Maximilians University Munich. He is a board-certified internist and endocrinologist and an Adjunct Professor of Internal Medicine at the Ludwig-Maximilians University Munich.

"The unique focus on improving the quality of life of underserved patients suffering from pain attracted me to Grünenthal," says Uli Brödl. "I look forward to joining the team and further driving Grünenthal's innovation pipeline."

"With Uli, we have been able to attract an excellent leader," says Gabriel Baertschi, CEO of Grünenthal. "His extensive experience in R&D and commercial functions combined with Uli's drive to bring innovative medicines to patients will help us propel our vision of a world free of pain."

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.

More information: <https://www.grunenthal.com>

Follow us on:

LinkedIn: [Grünenthal Group](#)

Instagram: [grunenthal](#)

For further information, please contact:

Florian Dieckmann, Head Global Corporate Affairs & Communication

Tel.: +49 241 569-2555

Florian.Dieckmann@grunenthal.com

Media:



Related Sectors:

Medical & Pharmaceutical ::

Scan Me:



Company Contact:

—

[news aktuell](#)

E. desk@newsaktuell.de

W. <https://www.newsaktuell.de/>

[View Online](#)

Additional Assets:

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.newsaktuell.pressat.co.uk>